

# Effectiveness of high-frequency oscillatory ventilation for the treatment of neonatal meconium aspiration syndrome

Li-xia Hao, MB<sup>a</sup>, Fei Wang, MB<sup>b,\*</sup>

## Abstract

**Background:** The purpose of this study is to raise nonjudgmental awareness and attention to current experience of high-frequency oscillatory ventilation (HFOV) for the treatment of neonatal meconium aspiration syndrome (NMAS).

**Methods:** We will comprehensively search literature from the databases of Cochrane Library, PubMed, Embase, Web of Science, WorldSciNet, PsycINFO, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure from inception until July 1, 2019 without language limitation. We will also handle searching the bibliographies of all relevant studies found for unpublished literatures. Statistical analysis will be conducted using RevMan 5.3 software.

**Results:** The outcomes include function inhaled oxygen concentration, oxygenation index, arterial oxygen tension/alveolar arterial oxygen tension, partial pressure of oxygen, partial pressure of carbon dioxide, transcutaneous arterial oxygen saturation, duration of hospitalization, and adverse events.

**Conclusion:** This study will provide an exhaustive view of HFOV for treating infants with NMAS.

**PROSPERO registration number:** PROSPERO CRD42019140520.

**Abbreviations:** HFOV = high-frequency oscillatory ventilation, NMAS = neonatal meconium aspiration syndrome, PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analysis, RCTs = randomized controlled trials.

**Keywords:** effectiveness, high-frequency oscillatory ventilation, neonatal meconium aspiration syndrome, randomized controlled trial, safety

## 1. Introduction

Neonatal meconium aspiration syndrome (NMAS) is a very serious disease.<sup>[1–3]</sup> It often occurs prior, during or right after the delivery.<sup>[4–7]</sup> Although it is often not life-threatening, it can lead to some several health complications for the infants.<sup>[8–10]</sup> If such condition is severe or untreatable, it is very fatal for the infants.<sup>[8–12]</sup> It often happens when the infants experience stress from pregnancy mothers that goes past the due date for more than 4 weeks, difficulty delivery or long labor, infection, and certain health problems experienced by the pregnant mother.<sup>[13–18]</sup> If it occurs, infants often manifest as rapidly breath or grunt during

breathing, or even stop breathing, and may also follows the symptoms of cyanosis, limpness, and low blood pressure.<sup>[4–6,15–17]</sup> High-frequency oscillatory ventilation (HFOV) has been reported to treat such condition very effectively.<sup>[1,9,18–21]</sup> However, there is still insufficient evidence to support it on the evidence-based medicine level. Therefore, this study will investigate the effectiveness and safety of HFOV for the treatment of infants with NMAS.

## 2. Methods

### 2.1. Eligibility criteria for study selection

**2.1.1. Types of studies.** We intend to include randomized controlled trials (RCTs) of HFOV for the treatment of NMAS. We will include Non-RCTs and quasi-RCTs, and case studies.

**2.1.2. Types of interventions.** The intervention measures taken by the experimental group must be HFOV.

The control group receives any different treatments from the experimental group.

**2.1.3. Types of participants.** Participants with a clinical diagnosis of NMAS will be included with no restrictions of race, gender, country, and sources.

**2.1.4. Types of outcome measurements.** The outcomes consist of function inhaled oxygen concentration, oxygenation index, arterial oxygen tension/alveolar arterial oxygen tension, partial pressure of oxygen, partial pressure of carbon dioxide, transcutaneous arterial oxygen saturation, duration of hospitalization, and adverse events.

*This study was partly funded by the Yan'an Specialized Project for Transformation and Promotion of Achievements (2018CGZH-15). The funder had no role in this study.*

*The authors have no conflicts of interest to disclose.*

<sup>a</sup> Department of Neonatology, <sup>b</sup> Department of Ophthalmology, Yan'an University Affiliated Hospital, Yan'an, China.

\* Correspondence: Fei Wang, Department of Ophthalmology, Yan'an University Affiliated Hospital, No 43, North Street, Baota District, Yan'an, Shaanxi 716000, China (e-mail: 122272455@qq.com).

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Hao Lx, Wang F. Effectiveness of high-frequency oscillatory ventilation for the treatment of neonatal meconium aspiration syndrome. *Medicine* 2019;98:43(e17622).

Received: 23 September 2019 / Accepted: 24 September 2019

<http://dx.doi.org/10.1097/MD.00000000000017622>

**Table 1**  
**Search strategy used in Cochrane Library database.**

Number	Search terms
1	MeSH descriptor: (meconium aspiration syndrome) explode all trees
2	MeSH descriptor: (infant, newborn) explode all trees
3	((infant <sup>*</sup> ) or (newborn <sup>*</sup> ) or (newborn infant <sup>*</sup> ) or (neonatal <sup>*</sup> ) or (meconium <sup>*</sup> ) or (aspiration <sup>*</sup> ) or (syndrome <sup>*</sup> ) or (rapidly breath <sup>*</sup> ) or (or grunt during breathing <sup>*</sup> ) or (stop breathing <sup>*</sup> )):ti, ab, kw
4	Or 1–3
5	(high frequency oscillatory ventilation) explode all trees
6	((high frequency ventilation <sup>*</sup> ) or (oscillatory <sup>*</sup> ) or (frequency <sup>*</sup> ) or (ventilation <sup>*</sup> ) or (mechanical ventilation <sup>*</sup> ) or (constant distending pressure <sup>*</sup> )):ti, ab, kw
7	Or 5–6
8	MeSH descriptor: (randomized controlled trials) explode all trees
9	MeSH descriptor: (clinical trials as topic) explode all trees
10	((random <sup>*</sup> ) or (randomly <sup>*</sup> ) or (control <sup>*</sup> ) or (comparator <sup>*</sup> ) or (allocation <sup>*</sup> ) or (placebo <sup>*</sup> ) or (blind <sup>*</sup> ) or (trial <sup>*</sup> ) or (study <sup>*</sup> ) or (control <sup>*</sup> )):ti, ab, kw
11	Or 8–9
12	4 and 7 and 11

## 2.2. Search strategy

**2.2.1. Electronic databases sources.** We intend to carry out a literature search from Cochrane Library, PubMed, Embase, Web of Science, WorldSciNet, PsycINFO, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure from inception until July 1, 2019 without language limitation. During literature retrieval, information experts have provided help and guidance. To fully retrieve qualified studies, a comprehensive search strategy for Cochrane Library is shown in Table 1. We will also adapt identical search strategies to other electronic databases.

**2.2.2. Other literature sources.** We will also retrieve unpublished literatures, including dissertations, ongoing trials, and conference abstracts.

## 2.3. Study selection

The literature selection will be independently performed by 2 researchers. This study consists of 2 stages. First, we will make a preliminary selection by scanning the titles and abstracts. Second, we will read all remaining relevant studies for further selection based on the eligibility criteria. If there are difference opinions between 2 researchers, a 3rd researcher will help to reach an agreement by discussion. The study selection process is presented in the flowchart.

## 2.4. Data extraction

We will investigate the characteristics of different clinical trials qualitatively. All data extraction will be conducted by 2 researchers independently. Any different opinions between 2 researchers, a 3rd researcher will help to reach a consensus through discussion. The main extraction information consists of title, primary author, publication time, country, patients, study design, study methods, treatment details, outcomes, safety, and follow-up details.

## 2.5. Risk of bias assessment

Two researchers will assess risk of bias independently using Cochrane risk of bias tool based on the Cochrane Handbook for Systematic Review of Interventions. Assessment items include 7 aspects. If there are different opinions, a 3rd researcher will help to make the final decision by discussion.

## 2.6. Measurements of treatment effect

Continuous variables will be expressed as mean difference or standardized mean difference and 95% confidence intervals. Categorical variables will be calculated as risk ratio and 95% confidence intervals.

## 2.7. Heterogeneity assessment

Heterogeneity will be checked based on the  $I^2$  test.  $I^2 \leq 50\%$  indicates low heterogeneity, and a fixed-effects model is used. On the contrary,  $I^2 > 50\%$  indicates significant heterogeneity, and a random-effects model is utilized.

## 2.8. Data synthesis

Statistical analysis will be performed using RevMan 5.3 software. If there is low heterogeneity ( $I^2 \leq 50\%$ ), meta-analysis will be conducted if more than 2 studies reporting an outcome have similar study design, patients, methods, and outcomes. If there is high heterogeneity ( $I^2 > 50\%$ ), we will carry out subgroup analysis. If a meta-analysis still cannot be performed after subgroup analysis, a comprehensive narrative summary will be reported to describe the studies.

## 2.9. Subgroup analysis

We will carry out subgroup analysis to explore the source of heterogeneity according to the different treatments, comparators, and outcomes.

## 2.10. Sensitivity analysis

We will conduct sensitivity analysis to check stability of outcome results by removing low quality RCTs.

## 2.11. Publication bias

The potential publication bias of all studies will be evaluated by funnel plot and Egger regression test.<sup>[22,23]</sup>

## 2.12. Ethics and dissemination

The findings of this study based on the published evidence; thus, ethical approval is not inquired. We intend to publish this study at peer-reviewed journals.

### 3. Discussion

This study aims to systematically assess the effectiveness and safety of HFOV for the treatment of NMAS. It will provide a detailed and evidence-based overview of the effectiveness of function inhaled oxygen concentration, oxygenation index, and arterial oxygen tension/alveolar arterial oxygen tension, partial pressure of oxygen, partial pressure of carbon dioxide, transcutaneous arterial oxygen saturation, and duration of hospitalization. Results of this study will provide evidence base to the clinical practice for selecting HFOV for infants with NMAS.

#### Author contributions

**Conceptualization:** Li-xia Hao, Fei Wang.

**Data curation:** Li-xia Hao, Fei Wang.

**Formal analysis:** Li-xia Hao, Fei Wang.

**Investigation:** Fei Wang.

**Methodology:** Li-xia Hao.

**Project administration:** Fei Wang.

**Resources:** Li-xia Hao.

**Software:** Li-xia Hao.

**Supervision:** Fei Wang.

**Validation:** Li-xia Hao, Fei Wang.

**Visualization:** Li-xia Hao, Fei Wang.

**Writing – original draft:** Li-xia Hao, Fei Wang.

**Writing – review & editing:** Li-xia Hao, Fei Wang.

#### References

- [1] Groneck P, Speer CP. Meconium aspiration syndrome [in German]. *Z Geburtshilfe Neonatol* 1996;200:132–7.
- [2] Srinivasan HB, Vidyasagar D. Meconium aspiration syndrome: current concepts and management. *Compr Ther* 1999;25:82–9.
- [3] Klingner MC, Kruse J. Meconium aspiration syndrome: pathophysiology and prevention. *J Am Board Fam Pract* 1999;12:450–66.
- [4] Wiedemann JR, Saugstad AM, Barnes-Powell L, et al. Meconium aspiration syndrome. *Neonatal Netw* 2008;27:81–7.
- [5] Fanaroff AA. Meconium aspiration syndrome: historical aspects. *J Perinatol* 2008;28(Suppl 3):S3–7.
- [6] Robertson NR. The management of meconium aspiration syndrome. *Turk J Pediatr* 1991;33:65–78.
- [7] Co E, Vidyasagar D. Meconium aspiration syndrome. *Compr Ther* 1990;16:34–9.
- [8] Chettri S, Bhat BV, Adhisivam B. Current concepts in the management of meconium aspiration syndrome. *Indian J Pediatr* 2016;83:1125–30.
- [9] Ogawa Y, Shimizu H. Current strategy for management of meconium aspiration syndrome. *Acta Paediatr Taiwan* 2000;41:241–5.
- [10] Socher R, Hagai M, Amitay M, et al. Meconium aspiration syndrome—risk factors and possible preventive measures [in Hebrew]. *Harefuah* 1992;122:716–20.
- [11] Hutton EK, Thorpe J. Consequences of meconium stained amniotic fluid: what does the evidence tell us? *Early Hum Dev* 2014;90:333–9.
- [12] Bhat RY, Rao A. Meconium-stained amniotic fluid and meconium aspiration syndrome: a prospective study. *Ann Trop Paediatr* 2008;28:199–203.
- [13] Mollnes TE, Castellheim A, Lindenskov PH, et al. The role of complement in meconium aspiration syndrome. *J Perinatol* 2008;28(Suppl 3):S116–9.
- [14] Xu H, Wei S, Fraser WD. Obstetric approaches to the prevention of meconium aspiration syndrome. *J Perinatol* 2008;28(Suppl 3):S14–8.
- [15] Lin HC, Wu SY, Wu JM, et al. Meconium aspiration syndrome: experiences in Taiwan. *J Perinatol* 2008;28(Suppl 3):S43–8.
- [16] Yurdakök M. Meconium aspiration syndrome: do we know? *Turk J Pediatr* 2011;53:121–9.
- [17] El Shahed AI, Dargaville PA, Ohlsson A, et al. Surfactant for meconium aspiration syndrome in term and late preterm infants. *Cochrane Database Syst Rev* 2014;CD002054.
- [18] Lindenskov PH, Castellheim A, Saugstad OD, et al. Meconium aspiration syndrome: possible pathophysiological mechanisms and future potential therapies. *Neonatology* 2015;107:225–30.
- [19] Bouziri A, Hamdi A, Khaldi A, et al. Management of meconium aspiration syndrome with highfrequency oscillatory ventilation. *Tunis Med* 2011;89:632–7.
- [20] Khatua S, Serrao PR, Milano EL. Advances in management of meconium aspiration syndrome. *Indian J Pediatr* 2000;67:837–41.
- [21] Gadzinowski J. Contemporary treatment options for meconium aspiration syndrome. *Croat Med J* 1998;39:158–64.
- [22] Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analyses. *BMJ* 2000;320:1574–7.
- [23] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629–34.